-
Product Insights
NewNet Present Value Model: TFF Pharmaceuticals Inc’s TFF VORI
Empower your strategies with our Net Present Value Model: TFF Pharmaceuticals Inc's TFF VORI report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AVA-6000 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AVA-6000 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AVA-6000 in Pancreatic Ductal Adenocarcinoma Drug Details: AVA-6000 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AVA-6000 in Metastatic Biliary Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AVA-6000 in Metastatic Biliary Tract Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AVA-6000 in Metastatic Biliary Tract Cancer Drug Details: AVA-6000...
-
Product Insights
NewNet Present Value Model: Pfizer Inc’s PF-06480605
Empower your strategies with our Net Present Value Model: Pfizer Inc's PF-06480605 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Systemic Aspergillosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Systemic Aspergillosis - Drugs In Development, 2023’, provides an overview of the Systemic Aspergillosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systemic Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Lung Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Lung Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Lung Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lung Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Allergic Bronchopulmonary Aspergillosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Allergic Bronchopulmonary Aspergillosis - Drugs In Development, 2023’, provides an overview of the Allergic Bronchopulmonary Aspergillosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Bronchopulmonary Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Drugs In Development, 2023
Global Markets Direct’s, ‘Marburgvirus Infections (Marburg Hemorrhagic Fever) - Drugs In Development, 2023’, provides an overview of the Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Aspergillosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Aspergillosis - Drugs In Development, 2023’, provides an overview of the Aspergillosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Ebolavirus Infections (Ebola Hemorrhagic Fever) – Drugs In Development, 2023
Global Markets Direct’s, ‘Ebolavirus Infections (Ebola Hemorrhagic Fever) - Drugs In Development, 2023’, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...